Last reviewed · How we verify
PEG-3350 with Electolytes
PEG-3350 with Electrolytes is a marketed product developed by the Post Graduate Institute of Medical Education and Research, Chandigarh, with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and the protection offered by its key patent. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | PEG-3350 with Electolytes |
|---|---|
| Sponsor | Post Graduate Institute of Medical Education and Research, Chandigarh |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: